UY37844A - Inhibidores de mcl-1 macrocíclicos y métodos de uso - Google Patents

Inhibidores de mcl-1 macrocíclicos y métodos de uso

Info

Publication number
UY37844A
UY37844A UY0001037844A UY37844A UY37844A UY 37844 A UY37844 A UY 37844A UY 0001037844 A UY0001037844 A UY 0001037844A UY 37844 A UY37844 A UY 37844A UY 37844 A UY37844 A UY 37844A
Authority
UY
Uruguay
Prior art keywords
mcl
methods
macrocyclic inhibitors
formula
compounds
Prior art date
Application number
UY0001037844A
Other languages
English (en)
Inventor
R Kunzer Aaron
S Judd Andrew
J Souers Andrew
Anthony Mastracchio
Cheng Ji
Chunqiu Lai
M Sullivan Gerard
A Teske Jesse
D Wendt Michael
Patrick Brady
Wilfried Braje
Xiaohong Song
Tao Zhi-Fu
George Doherty
Frauke Pohlki
Michael MICHAELIDES
D Penning Thomas
Andreas Kling
Katja Jantos
Xilu Wang
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Publication of UY37844A publication Critical patent/UY37844A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente divulgación proporciona compuestos de Fórmula (I), en onde A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, e Y tienen cualquiera de los valores definidos en la memoria descriptiva, y sales farmacéuticamente aceptables de los mismos, que sean útiles como agentes en el tratamiento de enfermedades y afecciones, incluido el cáncer. También se proporcionan composiciones farmacéuticas que comprenden compuestos de Fórmula (I).
UY0001037844A 2017-08-15 2018-08-15 Inhibidores de mcl-1 macrocíclicos y métodos de uso UY37844A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545872P 2017-08-15 2017-08-15
US201762555477P 2017-09-07 2017-09-07
US201862692667P 2018-06-30 2018-06-30

Publications (1)

Publication Number Publication Date
UY37844A true UY37844A (es) 2019-03-29

Family

ID=65362706

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037844A UY37844A (es) 2017-08-15 2018-08-15 Inhibidores de mcl-1 macrocíclicos y métodos de uso

Country Status (11)

Country Link
US (2) US20200239494A1 (es)
EP (1) EP3668502A4 (es)
JP (1) JP2020531457A (es)
CN (1) CN111818916A (es)
AU (1) AU2018318692A1 (es)
BR (1) BR112020003200A2 (es)
CA (1) CA3073114A1 (es)
MX (1) MX2020001719A (es)
TW (1) TW201920193A (es)
UY (1) UY37844A (es)
WO (1) WO2019035927A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112739343A (zh) * 2017-08-15 2021-04-30 艾伯维公司 大环mcl-1抑制剂和使用方法
SG10202106345VA (en) 2017-08-15 2021-07-29 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
US20230081720A1 (en) 2019-05-20 2023-03-16 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
KR20220024694A (ko) * 2019-06-21 2022-03-03 얀센 파마슈티카 엔.브이. Mcl-1의 거대환식 억제제
WO2021236654A1 (en) * 2020-05-18 2021-11-25 The Johns Hopkins University Anti-cancer spirocyclic-guanidine compounds and uses thereof
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
CN113252829B (zh) * 2021-05-07 2023-09-22 镇江高等职业技术学校 一种灌溉水中盐酸乙脒的测定方法
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
CA3222269A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2276346T3 (en) * 2008-04-30 2017-02-27 Nat Health Research Institutes FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORAKINASE INHIBITORS
WO2012156756A2 (en) * 2011-05-19 2012-11-22 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN112739343A (zh) * 2017-08-15 2021-04-30 艾伯维公司 大环mcl-1抑制剂和使用方法
SG10202106345VA (en) * 2017-08-15 2021-07-29 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use

Also Published As

Publication number Publication date
MX2020001719A (es) 2020-11-06
EP3668502A1 (en) 2020-06-24
TW201920193A (zh) 2019-06-01
WO2019035927A1 (en) 2019-02-21
EP3668502A4 (en) 2021-01-13
JP2020531457A (ja) 2020-11-05
AU2018318692A1 (en) 2020-03-12
CA3073114A1 (en) 2019-02-21
CN111818916A (zh) 2020-10-23
US20230399340A1 (en) 2023-12-14
US20200239494A1 (en) 2020-07-30
BR112020003200A2 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
UY37842A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
UY37843A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
UY37844A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
UY39630A (es) Inhibidores de bromodominios
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CO2018011064A2 (es) Inhibidores de bromodominios
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
DOP2015000308A (es) Inhibidores de bromodominios
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
CO2019007888A2 (es) Inhibidores selectivos de jak1
MX2016007440A (es) Inhibidores del bromodominio.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
UY36123A (es) Derivados de carboxamida
ECSP18056196A (es) Derivados de indano
CL2016002870A1 (es) Derivados bicíclicos y composición farmacéutica que incluye los mismos
TR201813294T4 (tr) N-aril-2-amino-4-aril-pirimidin makrosi̇kli̇k poli̇eter türevleri̇ ve bunlarin flt3 ve jak i̇nhi̇bi̇törleri̇ olarak kullanimlari.
UY36958A (es) Compuestos para administración intracelular
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
CU20160170A7 (es) Derivados de carboxamida

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231110